08:13 AM EST, 01/08/2025 (MT Newswires) -- Jasper Therapeutics ( JSPR ) said Wednesday that preliminary data from an ongoing phase 1b/2a study of subcutaneously administered briquilimab as a treatment for chronic spontaneous urticaria showed "substantial reductions" in disease activity.

The company said the 49-patient study showed clinical responses as early as one week after the first dose as well as "durable" clinical responses across multiple doses.

Chronic spontaneous urticaria is a condition which causes hives to appear.

Jasper Therapeutics' ( JSPR ) shares were down 44% in recent premarket activity.